NCT02423525View on ClinicalTrials.gov

Safety Study of Afatinib for Brain Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2021

Conditions
Brain Cancer
Interventions
DRUG

Afatinib

Trial Locations (1)

90404

John Wayne Cancer Institute, Santa Monica

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Santosh Kesari

OTHER